Peptide Category Comparison: Glucagon vs Insulin – Technical Pros and Cons
Title: Peptide Category Comparison: Glucagon vs Insulin – Technical Pros and Cons Abstract: This analysis compares glucagon and insulin as distinct peptide categories, focusing on technical pros, cons, and market trends. Insulin dominates the diabetes market (projected $63B by 2028), while glucagon is niche for severe hypoglycemia ($5.2B CAGR 7.1%). Insulin analogs offer superior stability and half-life (e.g., degludec >42h vs glucagon’s 18min), but glucagon’s rapid onset (5-15min) is critical for emergency use. Key parameters: insulin’s purity >98% (HPLC) vs glucagon’s >95%. Brand leaders (Novo Nordisk, Eli Lilly) hold FDA/EMA certifications. Logistics require cold-chain (2-8°C) for both. Selection tips: prioritize stability for insulin, speed for glucagon. Industry trends favor dual-action peptides and biosimilars.